Abstract:
The autoimmune disease known as type 1 diabetes mellitus (T1DM) causes an
insulin deficit and consequent hyperglycemia by targeting and destroying the
body's own insulin-secreting islet cell. Without insulin, these people will
eventually go into diabetic ketoacidosis (DKA), a potentially fatal condition. One
of the emerging treatment options for treating T1DM is gene therapy. Insulin
injections has been the sole therapeutic option for all type I diabetics for over
eighty years. The usual treatment of type 1 diabetes is fraught with difficulties.
Although whole-pancreas transplantation has been effective for some individuals,
the procedure is technically challenging and has a high risk of complications.
Research into diabetes has so focused heavily on finding ways to produce an
endless supply of cells with glucose-responsive insulin secretion. This analysis
focuses on the current state and prospective future of gene therapy in the
management of T1DM. In this article, the potential of gene therapy for replacing
beta cells is discussed. New findings in beta cell development and growth as well
as gene delivery to beta cells, will be addressed. Implementing gene therapy for
T1DM, selecting suitable vector, Potential therapeutic and preventative T1DM
strategy for eliminate the need for daily insulin shots.
